Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Context: While individuals with diabetes appear to be at similar risk for SARS-CoV-2 infection to those without diabetes, they are more likely to suffer severe consequences, including death. Diabetic ketoacidosis (DKA) is a common and potentially lethal acute complication of diabetes arising from a relative insulin deficiency, which occurs more often in those with type 1 diabetes and in the setting of moderate to severe illness. Early reports indicate that among patients with pre-existing diabetes, DKA may be a common complication of severe COVID-19 and a poor prognostic sign. Case Description: This clinical perspective explores the key elements of caring for individuals with DKA during the COVID-19 pandemic through 2 cases. Topics addressed include diagnosis, triage, and the fundamental principles of treatment with a focus on the importance of characterizing DKA severity and medical complexity to determine the best approach. Conclusions: As discussed, some tenets of DKA management may require flexibility in the setting of COVID-19 due to important public health goals, such as preventing transmission to highest risk individuals, reducing healthcare worker exposure to infected patients, and preserving personal protective equipment. Evidence for alternative treatment strategies is explored, with special attention placed on treatment options that may be more relevant during the pandemic, including use of subcutaneous insulin therapy. Finally, DKA is often a preventable condition. We include evidence-based strategies and guidance designed to empower clinicians and patients to avoid this serious complication when possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171 · cited 1×
“5% of patients who died had diabetes, a prevalence greater than 3 times that of the general population.(23) In Chinese cohorts, ICU care was more often required for patients with diabetes (22.”
BackgroundHyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444 · cited 2×
“Although substantive data on insulin requirements during COVID-19 is not yet published, clinicians have observed higher than usual insulin needs (up to 4 units/kg/day) in critically ill patients with COVID-19 (44)In addition, as described elsewhere,(9) the concomitant use of vasopressors or corticosteroids can signifi…”
BackgroundStentz, F. B., Umpierrez, G. E., Cuervo, R., & Kitabchi, A. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2079 · Cited by 497 · cited 3×
“DKA itself is an inflammatory state,(2) but is”
BackgroundInfluentialUmpierrez, G. E., Latif, K., Stoever, J., Cuervo, R., Park, L., X. Freire, A., & E. Kitabchi, A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.010 · Cited by 236 · cited 1×
“1 units/kg Umpierrez, et al (2004)(58) Patients with uncomplicated DKA”
BackgroundTreatment of diabetic ketoacidosis with subcutaneous insulin aspart
Umpierrez, G. E., Cuervo, R., Karabell, A., Latif, K., Freire, A. X., & Kitabchi, A. E. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1873 · Cited by 227
Barker, J. M., Goehrig, S. H., Barriga, K., Hoffman, M., Slover, R., Eisenbarth, G. S., Norris, J. M., Klingensmith, G. J., & Rewers, M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1399 · Cited by 220
Zhong, V. W., Juhaeri, J., & Mayer-Davis, E. J. (2018) · Diabetes Care · doi:10.2337/dc17-1583 · Cited by 177 · cited 1×
“In both the United States and the United Kingdom, DKA hospitalizations have risen sharply in the last decade, despite a decrease in the early part of this century (5, 6).”
BackgroundHamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126 · cited 1×
“8% of non-users.(39) Precipitating factors include acute illness with poor oral intake, vomiting, fasting, and reductions in insulin doses related to improved glycemic control (or missing doses during illness).”
BackgroundHsia, E., Seggelke, S., Gibbs, J., Hawkins, R. M., Cohlmia, E., Rasouli, N., Wang, C., Kam, I., & Draznin, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1244 · Cited by 112 · cited 2×
“While there are numerous publications on how to avoid poor transitions, perhaps the most innovative and practical one tested the impact of administering long-acting subcutaneous insulin, for example, glargine, in the early phases of DKA treatment, and during IVI, in order to prevent rebound ketoacidosis and/or marked…”
BackgroundPeters, A. L., Henry, R. R., Thakkar, P., Tong, C., & Alba, M. (2016) · Diabetes Care · doi:10.2337/dc15-1995 · Cited by 106
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Management of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329
Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14805 · Cited by 37
Wallia, A., Prince, G., Touma, E., El Muayed, M., & Seley, J. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01366-0 · Cited by 23
Karavanaki, K., Rodolaki, K., Soldatou, A., Karanasios, S., & Kakleas, K. (2022) · Endocrine · doi:10.1007/s12020-022-03266-7 · Cited by 20
Metadata
- Authors
- Palermo, N. E., Sadhu, A. R., & McDonnell, M. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-06-18
- Volume
- 105
- Issue
- 8
- Pages
- 2819-2829
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3035899256
- Cited by
- 123
- References
- 13
- FWCI
- 16.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.